Trial Profile

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE) in Cystic Fibrosis Patients With Chronic Infections Due to Pseudomonas Aeruginosa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amikacin (Primary)
Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Focus Adverse reactions
Sponsors Transave

Most Recent Events

18 Jun 2010 Status changed from recruiting to completed.
18 Jun 2010 Results of the open-label extension of this trial have been presented at the 33rd European Cystic Fibrosis Society (ECFS), according to a Transave media release.
13 Jun 2008 Added Transave as a sponsor, from Transave media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com